Expression of α-Klotho protein in human thyroid cancers - an immunohistochemical study.


Journal

Endokrynologia Polska
ISSN: 2299-8306
Titre abrégé: Endokrynol Pol
Pays: Poland
ID NLM: 0370674

Informations de publication

Date de publication:
2019
Historique:
received: 05 10 2018
accepted: 10 12 2018
pubmed: 31 1 2019
medline: 18 12 2019
entrez: 31 1 2019
Statut: ppublish

Résumé

The α-Klotho protein was discovered as a gene controlling the process of aging, but further studies indicated that it also plays the role of a tumour suppressor. Although numerous studies were performed on the role of the α-Klotho gene and protein in neoplasia, the data on α-Klotho protein expression in thyroid cancers are very scarce. Our study presents the immunohistochemical investigation of α-Klotho expression in benign and malignant thyroid tumours. The material included samples of benign (nodular hyperplasia, follicular adenoma), differentiated (follicular and papillary) cancers and aggressive thyroid cancers of low differentiation grade. The samples were immunostained using two different monoclonal anti-α-Klotho antibodies. From the two antibodies used in this study, one (EPR6856) reacted probably with the soluble form of Klotho and immunostained mostly the colloid filling thyroid follicles and intravascular or extravascular serum deposits. The other (A-9 antibody) immunostained the follicular epithelium in benign thyroid lesions as well as the epithelial tumoural cells in differentiated thyroid (follicular and papillary cancers). In the thyroid cancers of high malignancy, the immunostaining with A-9 anti-α-Klotho antibody was (except in one case) negative or very weak. Our results indicate that lowered expression of a- Klotho is involved in the process of thyroid neoplasia.

Identifiants

pubmed: 30699231
pii: VM/OJS/J/60348
doi: 10.5603/EP.a2019.0004
doi:

Substances chimiques

Glucuronidase EC 3.2.1.31
Klotho Proteins EC 3.2.1.31

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-240

Auteurs

Marek Pawlikowski (M)

Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Poland. marek.pawlikowski@umed.lodz.pl.

Hanna Pisarek (H)

Department of Neuroendocrinology, Interdepartmental Chair of Laboratory and Molecular Diagnostics, Medical University of Lodz, Poland.

Magdalena Borkowska (M)

Department of General and Endocrinological Surgery, Copernicus Memorial Hospital, Lodz, Poland.

Katarzyna Winczyk (K)

Department of Neuroendocrinology, Interdepartmental Chair of Laboratory and Molecular Diagnostics, Medical University of Lodz, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH